Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04531943 · ClinicalTrials.gov registry record
Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 285
- Enrollment target
NCT04531943 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 285 participants.
The verdict
NCT04531943 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 285 participants
- Enrollment target
Study Summary
The overarching goal of this research study is to achieve a better understanding of the rectal mucosal effects of feminizing hormones in people assigned male sex at birth and currently taking feminizing hormones who have sex with men. Better understanding the rectal mucosa in this population will allow for the optimization of current biomedical HIV prevention interventions and enhance design of future interventions, including an effective HIV vaccine. This study will recruit approximately 520 transgender women who have receptive anal intercourse with men (TGWSM) and cis-gender men into one of two cohorts. Cohort 1 is a cross-sectional study and Cohort 2 is a longitudinal study; enrollment into each cohort is based on participant characteristics.
Interventions
- DRUG Estrogen
- DRUG Estrogen plus Progesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2024-04-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04531943
The ClinicalTrials.gov registry entry for NCT04531943 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Estrogen is the first listed.
NCT04531943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04531943 about?
NCT04531943 is a clinical study titled "Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women". The overarching goal of this research study is to achieve a better understanding of the rectal mucosal effects of feminizing hormones in people assigned male sex at birth and currently taking feminizing hormones who have sex with men. Better understanding the rectal mucosa in this population will al...
What is the current status of trial NCT04531943?
This trial is currently completed. The enrollment target is 285 participants. The study started on 2020-10-01. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT04531943?
The interventions under investigation include: Estrogen (DRUG), Estrogen plus Progesterone (DRUG).
Who is sponsoring clinical trial NCT04531943?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.